

THE STATE OF THE COVID-19 PANDEMIC IN ALAMEDA COUNTY

FEBRUARY 25, 2021 * SOPHY S. WONG, MD

WELCOME! PLEASE INTRODUCE YOURSELF
WITH YOUR NAME, ROLE AND AGENCY INTO THE CHAT.
PLEASE HELP US COMPLETE THE POLL.
WHAT'S ON YOUR MIND AROUND COVID TODAY?

HealthPAC
Health Program of Alameda County

EAST BAY GETTING TO ZERO

AETC AIDS Education & Training Center Program Pacific

COMMUNITY HEALTH CENTER NETWORK

No faculty/presenters, planners, including CME committee members, have relative financial relationships with commercial interests.

The Community Health Center Network is accredited by California Medical Association (CMA) to provide continuing medical education for physicians.

CHCN designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit (s)™*.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AETC AIDS Education & Training Center Program Pacific

CEUs for RNs:

- This course meets the qualifications for 1.5 contact hours of continuing education credit for nurses as required by the California Board of Registered Nursing, Provider # CPE 13741.

CEUs for behavioral health professionals:

- Bay Area North & Central Coast AIDS Education & Training Center is approved by the California Association of Marriage and Family Therapists (CAMFT) to sponsor continuing education for LMFTs, LCSWs, LPCCs, and/or LEPs. Bay Area North & Central Coast AIDS Education & Training Center maintains responsibility for this program/course and its content. This course meets the qualifications for 1.5 hours of continuing education credit for LMFTs, LCSWs, LPCCs, and/or LEPs as required by the California Board of Behavioral Sciences, Provider # 133640. Any activities within the program that do not have instructional time are not offered for continuing education credit. Course completion certificates will be awarded upon completion of course evaluations. *Documentation must be retained by the Participant for a period of four years after the conclusion of this program.*

Learning objectives:

1. Review the current state of the COVID-19 pandemic in Alameda County, including case trends, transmission rates, variants and disparities.
2. Discuss the current state of the COVID-19 vaccine roll-out and access in Alameda County.
3. Determine prevention strategies you will use and support clients with.

San Francisco Chronicle e-edition

As nation marks half a million deaths, concerns rise over new California coronavirus variant

Erin Allday
Feb. 22, 2021 | Updated: Feb. 22, 2021 7:44 p.m.

1 of 3

Romelia Navarro (right) is comforted by nurse Michele Younkin at the bedside of her dying husband in a Fullerton hospital.

Jae C. Hong / Associated Press

San Francisco Chronicle e-edition

Key reasons coronavirus cases are plunging across the Bay Area and California



Source: California Department of Public Health

Todd Trumbull / The Chronicle

COVID-19 VACCINES IN ALAMEDA COUNTY



%>=16 Years Received First Dose	%>=16 Years Fully Vaccinated
18.6%	6.4%

# of First Doses Administered	# of Second Doses Administered
244641	83316

Data from ACPHD COVID dashboard: vaccination rates (2/24/21)

COVID-19 DISPARITIES: ALAMEDA COUNTY CASES



Includes City of Berkeley
Cases source: CalREDIE Data Distribution Portal download February 11, 2021 8:00 am.

Alameda County Health Care Services Agency
Alameda County Public Health Department
Celebrating Healthy People in Healthy Communities

COVID-19 DISPARITIES: ALAMEDA COUNTY DEATHS



Alameda County case and death rates (2/24/21): Latinx people are 4x more likely to be diagnosed with COVID-19 and Black/African American residents are nearly 2x more likely to die from COVID-19 compared to their white neighbors.

COVID-19 DISPARITIES: ALAMEDA COUNTY VACCINES



Alameda County case and vaccination rates (2/24/21): Latinx and Black/African American residents are more likely to get and die from COVID-19 yet white and Asian residents are more likely to have been vaccinated.

VARIANTS: VIRUSES MUTATE WHEN THEY REPLICATE



- Cal.20c variants
- Lineage: B.1427/9
- Mutation: L452R
- Frequency in the Bay Area increased from 3% (Nov) to >50% (Jan).
- Increased household transmission: 26→35%
- Association with ICU, death

Infographic above left is from the EU CDC, updated 2/8/2021;
Info on CA variants from 2/22/21 Unidos en Salud + UCSF studies and 2/17/21 ACPHD EOC meeting

VARIANTS: VIRUSES MUTATE WHEN THEY REPLICATE



Variants in Alameda County:

- **The UK variant** (B117)**:** 7 cases
- **The South African variant** (B1351): 1 case
- No cases of the Brazilian variant (P1) identified yet

- Cal.20c variants
- Lineage: B.1427/9
- Mutation: L452R
- Frequency in the Bay Area increased from 3% (Nov) to >50% (Jan).
- Increased household transmission: 26→35%
- Association with ICU, death

Infographic above left is from the EU CDC, updated 2/8/2021;
Info on CA variants from 2/22/21 Unidos en Salud + UCSF studies and 2/17/21 ACPHD EOC meeting

VARIANTS: VIRUSES MUTATE WHEN THEY REPLICATE

Breaking news on the CA variants:

- Frequency in the Bay Area increased from 3% (Nov) to >50% (Jan).
- Increased household transmission by ~35%
- Possible association with ICU, death
- Vaccines expected to remain effective

Mission District residents are swabbed for COVID-19 at a pop up test site in front of 24th Mission Bart Station in early December. Continued testing in the area show that a new variant has become much more widespread. *Photo by Mike Kai Chen*



- Cal.20c variants
- Lineage: B.1427/9
- Mutation: L452R
- Frequency in the Bay Area increased from 3% (Nov) to >50% (Jan).
- Increased household transmission: 26→35%
- Association with ICU, death

Info on CA variants from 2/22/21 Unidos en Salud + UCSF studies and 2/3/21 ACPHD EOC meeting

COVID-19 PREVENTION: A RACE AGAINST MUTANTS!

COVID-19 harm reduction strategies: Use as many of these as you can!

Strategy	% reduction
1. Vaccination	95% mRNA EUA vaccines
2. Masking	60-95%
3. Staying outdoors	~95% in one case series
4. Distancing	53-88%
5. Eye protection	78%
6. Hand hygiene	28-45%
7. Testing/isolation	33%

Updated 12.23.20 * Data compiled by Sophy S. Wong, MD
Icons by Good Ware, Freepik and Srip on Flaticon.com
Please see EBGTZ.org/resources for the complete list of sources for this table.

WEEKLY UPDATES:
EBGTZ.ORG/COVID

EAST BAY GETTING TO ZERO

YOU LOOK FANTASTIC WHEN YOU MASK IT!

SHOULD I DOUBLE-MASK?

Wearing two masks on top of each other (double-masking) and 3+ layered masks can provide more protection so long as you can keep them tight on your face.

Diagram from "Uniting Infectious Disease and Physical Science Principles on the Importance of Face Masks for COVID-19," by Dr. Monica Gandhi and Linsey C. Marr. Scientific references for these masking tips are located here.

Figure 1. Recommended Masks for Public
Top: basic; bottom: maximal protection.

Wearing a mask that fits tightly to your face can help limit spread of the virus that causes COVID-19
In lab tests with dummies, exposure to potentially infectious aerosols decreased by about 95% when they both wore tightly fitted masks
Cloth mask over medical procedure mask
Medical procedure mask with knotted ear loops and tucked-in sides
Other effective options to improve fit include:
Mask fitter
Nylon covering over mask
CDC.GOV
bit.ly/MMWR21021
MMWR


REDUCING THE RISK OF COVID-19 WHEREVER YOU ARE
The safest way to reduce the spread of COVID-19 is to stay home and connect with others via phone or video.
If you gather in person, wear a mask and keep it outside, small and short with a stable group of people.
LOWER RISK
OUTDOOR
·≥6' Distance
·Masks ON
WALKS
RUNNING
HIKING
BIKING
MODERATE RISK !
OUTDOOR
·<6' Distance
·Masks Off
PICNICS OR BBQS
OUTDOOR GATHERINGS
OUTDOOR DINING
HIGHER RISK !!
INDOOR
·Distanced ·Fewer People
·Masks On ·Ventilation
STORES
RELIGIOUS SPACES
DOCTOR'S OFFICES
HIGHEST RISK !!!
INDOOR
·Crowds ·<6' Distance
·Masks Off ·Less Ventilation
BARS OR RESTAURANTS
GYMS
INDOOR PARTIES
HOTELS
COFFEE SHOPS
BEST TO:
WEAR ANY FACE COVERING
KEEP IT ≤3 HOUSEHOLDS
BEST TO DO AS MANY AS THE FOLLOWING AS YOU CAN:
WEAR A MASK
WEAR GLASSES
KEEP >6 FT DISTANCE
KEEP IT ≤3 HOUSEHOLDS
KEEP IT SHORT <2 HRS
OPEN WINDOWS FOR VENTILATION
STAY IN MORE SPACIOUS AREAS
AVOID WHEN POSSIBLE BUT IF YOU ATTEND:
EAST BAY GETTING TO ZERO

COVID-19 MRNA VACCINES: HOW THEY WORK







Images from BBC.com and *SF Chronicle Explainer*

COVID-19 MRNA SNAPCHAT VACCINES





Images from Flaticon (mynamepong) and *SF Chronicle Explainer*

Company	Platform	Doses	Non-clinical results	Number of people who got vaccine	Protection from hospitalization due to COVID-19	Protection from severe disease from COVID-19 (may not be hospitalized)	Efficacy against milder disease from COVID-19
moderna	mRNA-1273 mRNA in lipid nanoparticle	2	Neutralizing Abs; Strong Th1 CD4+, CD8+; protection from challenge (macaques)	~15,000	97% (1 in vaccine arm after 1st dose hospitalized)	97% (30 cases in placebo arm; 0 in vaccine reported but 1 severe per FDA)	94.1%
Pfizer	BNT162b2 mRNA in lipid nanoparticle	2	Neutralizing Abs; Strong Th1 CD4+, CD8+; protection from challenge (macaques)	~18,600	100%	100% (9 cases in placebo arm; 0 in vaccine- 1 initially severe but not)	95%
Johnson&Johnson	JNJ-78436725 Non-replicating human adenovirus/DNA	1	Neutralizing Abs; Strong Th1 CD4+ > Th2; CD8+; challenge protection (macaque)	~22,000 US, Latin America, S. Africa	100%	85% across 3 sites (89% in South Africa – 95% of strains 501Y.V2)	72% US; 66% Latin America; 57% S. Africa (95% B1.351)
AstraZeneca	AZD 1222 Non-replicating Chimp Adenovirus-DNA	2	Neutralizing Abs; Strong Th1 CD4+ > Th2; CD8+; protection from challenge (macaques)	~8588	100%	100% (15 in placebo – all hospitalized; 0 in vaccine)	70% overall; 76% 1 dose; S. Africa trial halted for mild
NOVAVAX	NVX-CoV2373 Spike protein/RBD + Matrix M adjuvant	2	Neutralizing Abs; Strong Th1 CD4 > Th2; challenge protection (macaques)	~9700 (Phase 3 UK; 2b SA)	100%	100% (but only 1 severe in placebo; 0 in vaccine)	89.3% UK; 60% S. Africa (94% B.1.351)
Sputnik V	Ad26 and Ad5 adenovirus/DNA	2	NAbs; IFN-γ secretion PMBCs, cellular response	~14964	100%	100% (20 in placebo; 0 vaccine)	91.6%

Slide from Dr. Monica Gandhi, UCSF

Company	Platform	Doses	Non-clinical results	Number of people who got vaccine	Protection from hospitalization due to COVID-19	Protection from severe disease from COVID-19 (may not be hospitalized)	Efficacy against milder disease from COVID-19
moderna	Of the 6 vaccines with clinical trial data overall reductions in infections were:			**Bottom line:**			
Pfizer	• 94%: Moderna			**100% protection against hospitalization after full vaccination!**			
Johnson&Johnson	• 95%: Pfizer (94% real-world)						
AstraZeneca	• 72%: J&J in US						
NOVAVAX	• 70% AstraZeneca						
Sputnik V	• 89% Novavax						
	• 92% Sputnik						

COVID-19 VACCINES: WHAT ABOUT VARIANTS?

- Lab and clinical trial data show less efficacy against mild-moderate disease in South African variant.
- **Still high enough titers of antibodies in lab studies.**
- **100% effective in clinical trials against hospitalization/death**.

COVID-19 VACCINES: PREVENT TRANSMISSION?

- Data suggest that vaccinated people have lower likelihood of transmitting the virus:
- Hot off the press! Data from 1.2 million people in Israel suggest a 90% reduction in asymptomatic infection. (Dagan, 2/24/21)
- Lower viral loads when infected (↓4-10x).
- Asymptomatic infection and lower viral loads are linked to less viral spread.


The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan, M.D., Noam Barda, M.D., Eldad Kepten, Ph.D., Oren Miron, M.A., Shay Perchik, M.A., Mark A. Katz, M.D., Miguel A. Hernán, M.D., Marc Lipsitch, D.Phil., Ben Reis, Ph.D., and Ran D. Balicer, M.D.

COVID-19 MRNA VACCINE: WHAT ABOUT SAFETY?

CDC study of 14 million doses and 1.6 million reports (VAERS and v-safe)

- **Anaphylaxis was rare**: 4.5 cases per million doses (0.00045%)
- **Death was not linked**: People who died after receiving the vaccine were not found to have a causal relationship with vaccination.
- **Most common side effects** or adverse reactions (more after 2nd dose):
  - 71% injection site pain
  - 34% fatigue
  - 30% headache
  - 23% muscle aches
  - 11-12% chills, fever, injection site swelling

COVID-19 MRNA VACCINE SAFETY

CDC study of 1.6 million people from VAERS and v-safe (2/19)

- **Anaphylaxis was rare**: 4.5 cases per million doses (0.00045%)
- **Death was not linked**: People who died after receiving the vaccine were not found to have a causal relationship wi
- **Most common side effects** or adverse re se):
  - 71% injection site pain
  - 34% fatigue
  - 30% headache
  - 23% muscle aches
  - 11-12% chills, fever, injection site swelling

This is our immune system training to protect us from COVID-19!

COVID-19 VACCINES: US TRIAL DEMOGRAPHICS

Table 1: Race/Ethnicity of Participants in Pfizer-BioNTech and Moderna COVID-19 Vaccine Clinical Trials

	Total US Population Age 16+	Pfizer-BioNTech*	Moderna
Total	**258 million**	**40,277**	**27,817**
Race			
White	73.6%	81.9%	79.4%
Black	12.3%	9.8%	9.7%
Asian	5.9%	4.4%	4.7%
American Indian/Alaska Native	0.8%	0.6%	0.8%
Native Hawaiian or Other Pacific Islander	0.2%	0.2%	0.2%
Ethnicity			
Hispanic	17.6%	26.2%	20.0%
Non-Hispanic	82.4%	73.2%	79.1%

NOTES: *Pfizer-BioNTech data are for all participants globally; of which 76.7% are in the United States. Pfizer results provided for Phase 2/3 trial, Moderna results for Phase 3 trial. The Pfizer trial included those ages 16 and older. The Moderna trial included those ages 18 and older.
SOURCES: Racial/ethnic distribution of total population age 16 or older based on KFF analysis of 2019 American Community Survey data; FDA, Briefing Document: Pfizer-BioNTech COVID-19 Vaccine, December 10, 2020; FDA, Briefing Document: Moderna COVID-19 Vaccine, December 17, 2020

Onyema Ogbuagu, MD; Yale/Pfizer study lead

Kizzmekia Corbett, PhD; NIAID/Moderna lead

Table from Kaiser Family Foundation, 1/26/21

COVID-19 VACCINES: US TRIAL DEMOGRAPHICS

Table 1: Race/Ethnicity of Participants in Pfizer-BioNTech and Moderna COVID-19 Vaccine Clinical Trials

	Total US Population Age 16+	Pfizer-BioNTech*	Moderna
Total			
Race			
White			
Black			
Asian			
American Indian/Alaska Nati			
Native Hawaiian or Other Pa			
Ethnicity			
Hispanic			
Non-Hispanic			

NOTES: *Pfizer-BioNTech da
trial, Moderna results for Ph
SOURCES: Racial/ethnic distr
Briefing Document: Pfizer-Bi
17, 2020

- Black/African Americans: 10%
- Latinx Americans: 20-26%
- Asian Americans: 4-5%
- Native Americans: 0.6-0.8%
- Native HI/Pacific Islanders: 0.2%

Onyema Ogbuagu, MD; Yale/Pfizer study lead

Kizzmekia Corbett, PhD; NIAID/Moderna lead

Table from Kaiser Family Foundation, 1/26/21

Alameda County Vaccine Prioritization

Alameda County is now vaccinating:

- Health Care Workers
- People in Long Term Care Facilities
- People ages 65+
- Food/Agriculture/Restaurant/Grocery workers
- Emergency Services workers
- Education/Childcare workers

Within each category, prioritizing:

- Older adults
- MediCal or Uninsured
- Areas with very high COVID-19 case rates (HPI Q1 + priority zip codes)
- People with direct contact with clients or the public at work
- People who cannot work from home
- People with limited mobility

Appointments by invitation

Sign up for notification: https://covid-19.acgov.org/vaccines

Alameda County Health Care Services Agency | Alameda County Public Health Department — Celebrating Healthy People in Healthy Communities

State Update: Expanded Eligibility for Vaccine as of 3/15/21

People with underlying medical conditions:

- Cancer
- Chronic kidney disease (stage 4 and above)
- Chronic pulmonary disease (oxygen dependent)
- Down syndrome
- Immunocompromised state from solid organ transplant
- Pregnancy
- Sickle cell disease
- Heart conditions (excludes hypertension)
- Severe obesity (Body Max Index ≥ 40kg/m2)
- Type 2 diabetes mellitus (with hemoglobin A1c level greater than 7.5%)

OR

If as a result of a developmental or other severe high-risk disability one or more of the following applies:

- Individual is likely to develop severe life-threatening illness or death from COVID-19 infection
- Acquiring COVID-19 will limit the individual's ability to receive ongoing care or services vital to their well-being and survival
- Providing adequate and timely COVID care will be particularly challenging due to individual's disability

Alameda County Health Care Services Agency | Alameda County Public Health Department — Celebrating Healthy People in Healthy Communities

REASONS FOR DECLINING VACCINES AT ALAMEDA COUNTY SITES

- Fear of how new and how quickly the vaccines were developed.
- Fear of the vaccine being experimental.
- Fear of side effects and new technology; want to see how others do first.
- Not enough evidence or information about the vaccine yet.
- Belief that it's just a placebo effect: skepticism of efficacy.
- Belief you don't need a vaccine if you've had COVID.
- Belief that the vaccine gives you the virus.

WHAT ARE WE DOING TO INCREASE VACCINE CONFIDENCE & ACCESS FOR OUR PATIENTS?







ADDRESSING VACCINE DISPARITIES

Vacuna COVID-19

Escuela Fremont High
4610 Foothill Blvd, Oakland, CA 94601
Jueves a Sábado, Feb. 4 - 6, 8am - 4pm

Quienes

Trabajadores de Salud, Cuidado en el Hogar, y Servicios de Apoyo en el Hogar (IHSS)

Siguientes

Edades 65+, Trabajadores de Emergencia, Educación, Cuidado de Niños, Comida, y Agricultura

Regístrese

covid-19.acgov.org/vaccines

Protéjase

ALAMEDA COUNTY HEALTH CARE SERVICES AGENCY
PUBLIC HEALTH DEPARTMENT
@Dare2BWell

OAKLAND UNIFIED SCHOOL DISTRICT

01/29/2021 Spanish

BE Well
¡Es su turno!

Focus on communities with disproportionate COVID-19 impacts



Zip codes in priority neighborhoods

- ✓ San Antonio/Fruitvale - 94606, 94601
- **Next: East Oakland** - 94621, 94603
- **Next: Ashland/Cherryland** - 94578, 94541, 94580
- So. Hayward - 94544
- West Oakland – 94607
- Fremont

Alameda County Health Care Services Agency
Alameda County Public Health Department
Celebrating Healthy People in Healthy Communities

Vaccine capacity at Alameda County vaccination sites

Rolling POD Plan	Current capacity (week)	Full/ Next week
Community PODs		
Castro Valley Library	4,406	3,840
Fruitvale Fremont HS	1,800	1,920
New sites will be coming…		
FireHouse Pop-ups		
Fremont Fire	800	1,200
Union City	200	350
So. Hayward	1,000	1,000
San Lorenzo/Cherryland/Ashland (ACF)	1,200	3,000
Mega PODs		
Coliseum	31,000	42,000
Fairgrounds	3,248	36,000
Buchanan Parking Lot (AC/COB POD)	2,000	2,000
Closed		
Santa Rita Jail	480	960
Emergency Services: OES	1,100	2,200
Clinics		
Estimated Combined Total	5,000	5,000
Mobile		
Local Pharmacies	1,300	1,300
TOTAL	**47,234**	**97,470**

More info on vaccine access:

- www.ebgtz.org/covid-vaccines/
- https://covid-19.acgov.org/vaccines
- *Oaklandside*

Alameda County Health Care Services Agency

Alameda County Public Health Department
Celebrating Healthy People in Healthy Communities

BUILDING VACCINE CONFIDENCE: COMMUNITY SPOTLIGHTS



Moisés Cruz Jáuregui, EBGTZ, dice: **"**Una vacuna significa tener la posibilidad de prevenir una enfermedad. El COVID19 ha lastimado mucho nuestra comunidad y a la vez nos ha enseñado lo fuertes que podemos ser juntos. Tuve la oportunidad de recibir la vacuna y me siento muy agradecido y afortunado por mi mismo y por la comunidad con la trabajo. Cuando tengan la oportunidad, aprovechenla y opten por protegerse y proteger a los que aman!"

BUILDING VACCINE CONFIDENCE: COMMUNITY SPOTLIGHTS

Shirley Gainey, Cal-PEP: The reason I got vaccinated is that I miss hugging my baby boy… My landlord is 83 years old. I don't want to place him in harm's way. I miss going to campus. I am so over virtual everything!

BUILDING VACCINE CONFIDENCE: COMMUNITY SPOTLIGHTS



Jesse Brooks, EBGTZ/AHF: Being vaccinated was important to me, I can't wait to get back to some resemblance of normalcy. I miss my family, and especially my 86-year-old mother... As a community leader I felt the demonstration to the community and my family was important, knowing the mistrust that exists and knowing that it's a challenge to put those fears to rest.

Slide from Dr. Monica Gandhi, UCSF

BUILDING VACCINE CONFIDENCE: MESSENGERS

- **Trusted messengers: us!**
  - Medical providers
  - Community health workers, promotoras
  - Public health and medical professional organizations
  - Family members
  - Race/ethnicity concordance



BUILDING VACCINE CONFIDENCE: MESSAGES

- **Messages that resonate**
  - **Acknowledge distrust and racism.**
  - **Validate and address concerns.** Use plain, clear language to describe vaccine development and safety.
  - **Stick to the positive**: be inviting, respectful. "The choice is yours to make." Avoid demand, negativity, fear.
  - **Focus on how vaccines help family and community.** "This protects all of us so we can get together again."



BUILDING VACCINE CONFIDENCE: SYSTEMS

- **Share photos and testimonials with us!**
- **Counsel on vaccines at each visit**: any/all team members; billable with code Z71.89 (vax counseling) with a principal diagnosis code.
- **Set up systems for tracking outreach, acceptance/declines, doses.**
- **Follow-up with patients who decline** to address questions and concerns, especially with their most trusted team member.
- **Follow-up to make sure patients get vaccine dose #2.**

CASE : BUILDING VACCINE CONFIDENCE

Mr. Ramirez is a 60 year old Spanish-speaking cisman and grocery store worker with diabetes and living in a large extended family household. He had a mild case of COVID last summer and has questions on whether he should get the vaccine or not.

CASE : BUILDING VACCINE CONFIDENCE

Ms. Johnson is a 40 year old English-speaking transwoman living with HIV and a CD4 count of 180, smokes cigarettes, takes HIV medications and hormones and is concerned about vaccine safety.

QUESTIONS FOR DISCUSSION

WE'LL PUT THESE IN THE CHAT FOR REFERENCE.

1. What questions or concerns are on your mind around the pandemic?
2. What will you counsel clients on around masking and other harm reduction practices?
3. What is your plan for discussing vaccines with clients?
4. What was most useful for you?

CHECK OUT OUR WEEKLY UPDATES: WWW.EBGTZ.ORG/COVID

TO VOLUNTEER AT A COUNTY VACCINATION SITE: WWW.HEALTHCAREVOLUNTEERS.CA.GOV.

EAST BAY GETTING TO ZERO